SIgN Immunology Seminar



Dr Toh Han Chong

Division of Medical Oncology
National Cancer Centre Singapore

Immunity and Immuno-oncology for Virally-driven Cancers - the National Cancer Centre Singapore Experience

Host
Dr Subhra K. Biswas
Singapore Immunology Network, A*Star

Date
Friday
5 February 2016

Time
2pm – 3pm

Venue
SIgN Seminar Room
Immunos Building
Level 4
Biopolis

Dr Toh Han Chong is Senior Consultant and Deputy Director, National Cancer Centre Singapore (NCCS). He is Vice-Chair of Oncology Academic Clinical Program (ACP) for Education. He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS, and adjunct Principal Investigator, Institute of Molecular and Cell Biology, A*STAR. He is former Head, Division of Medical Oncology, NCCS and past president of the Singapore Society of Oncology and past chairman of the Chapter of Medical Oncology, Singapore and currently an Examiner for the National Residents Assessment Committee for Medical Oncology. He is a member of the Singapore Medical Association Council, and on the Ministry of Health Committee for Drug Evaluation.

Dr Toh graduated from the University of London, UK, with an Intercalated Bachelor of Science in 'Infection and Immunity' from St Mary's Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. He is also an alumni of Harvard Business School.

Dr Toh is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. He has given many plenary lectures both regionally and internationally mainly in the field of immuno oncology. He is one of three founding chairmen of the internationally recognised phase III adjuvant aspirin study in colorectal cancer (ASCOLT) that spans over 60 sites including in China, India, South Korea, Taiwan, Hong Kong and the entire Australia Gastro-intestinal Trials Group. Dr Toh is also the coordinating Principal Investigator for the world's first FDA randomized phase III trial of T cell therapy in any cancer indication. An expert in cancer drug development and clinical trials, he is the chairman of the advisory board for the SingHealth Investigational Medicine Unit, Singapore's largest and most active Phase I clinical trials centre.

Dr Toh has published over 82 peer review journal papers to date including in Nature Reviews Clinical Oncology, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research and Stem Cells.